Compare BFC & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFC | NNNN |
|---|---|---|
| Founded | 1894 | 2021 |
| Country | United States | Germany |
| Employees | N/A | 27 |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2025 |
| Metric | BFC | NNNN |
|---|---|---|
| Price | $128.24 | $34.00 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $142.00 | N/A |
| AVG Volume (30 Days) | ★ 62.3K | 37.8K |
| Earning Date | 01-20-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.11 | 0.06 |
| Revenue | ★ $168,778,000.00 | $8,185,146.00 |
| Revenue This Year | $11.79 | N/A |
| Revenue Next Year | $32.03 | N/A |
| P/E Ratio | ★ $17.85 | $619.66 |
| Revenue Growth | N/A | ★ 21.95 |
| 52 Week Low | $92.49 | $5.18 |
| 52 Week High | $139.71 | $55.65 |
| Indicator | BFC | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 54.45 |
| Support Level | $132.74 | $31.18 |
| Resistance Level | $137.56 | $35.55 |
| Average True Range (ATR) | 3.18 | 5.14 |
| MACD | -0.88 | 0.14 |
| Stochastic Oscillator | 1.53 | 37.79 |
Bank First Corp is a United States-based company engaged in providing financial services provides a full range of consumer and commercial financial institution services to individuals and businesses including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.